Investigating Its Role as an Immune Adjuvant in Cancer Immunotherapy TOKYO, Aug. 19, 2025 /PRNewswire/ — ARC Therapies Inc. (Head Office: Shinjuku, Tokyo; President & CEO: Rami Suzuki), a certified startup from the National Cancer Center Japan, has initiated research of YB328, a newly…
